Apogee Therapeutics, Inc.

APGE · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
51
SEC Filings

Business Summary

Overview We are a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of...

Next Earnings

Q2 FY2026 — expected 2026-08-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAPGEdiscussed_in_filing Healthcare & Bio
topic_mentionAPGEdiscussed_in_filing Healthcare & Bio
topic_mentionAPGEdiscussed_in_filing Healthcare & Bio
topic_mentionAPGEdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-022025-12-310001974640-26-000002EDGAR96K words
2025-03-032024-12-310000950170-25-030385EDGAR—
2024-03-052023-12-310001558370-24-002406EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-273260EDGAR62K words
2025-08-112025-06-300000950170-25-106234EDGAR—
2025-05-122025-03-310000950170-25-068513EDGAR—
2024-11-122024-09-300000950170-24-124559EDGAR—
2024-08-122024-06-300000950170-24-095053EDGAR—
2024-05-132024-03-310001558370-24-007861EDGAR—
2023-11-132023-09-300001558370-23-018692EDGAR—
2023-08-282023-06-300001558370-23-015278EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-250001104659-26-034579EDGAR29K words
2026-03-230001104659-26-032950EDGAR—
2026-03-020001974640-26-000001EDGAR—
2026-01-060001104659-26-001063EDGAR—
2025-11-100001193125-25-273250EDGAR—
2025-10-100001104659-25-098487EDGAR—
2025-08-110000950170-25-106228EDGAR—
2025-07-070001104659-25-065926EDGAR—
2025-06-230000950170-25-088600EDGAR—
2025-05-120001104659-25-046955EDGAR—

51 total filings indexed. 30 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001974640
TickerAPGE
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 76fd27de6a4ac41760961dfb08cfb695a656f374d1870061cdc5b71318020d10
parent: 7ff6b2b46e359af40f5b5a65811d48d9b73048a942e289e67094d941d13133cb
content hash: 363bfe580b36977bb723e9cf5524c6106ae707442e9a0efe41572cf74b6d0a5c
signed: 2026-04-13T04:43:40.970Z
sources: 11 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf